PEDIATRICS Vol. 79 No. 3 March 1987, pp. 321-325
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Black, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Black, S. B.

b-CAPSA I Haemophilus influenzae, Type b, Capsular Polysaccharide Vaccine Safety

Steven B. Black MD1, Henry R. Shinefield MD1, and The Northern California Permanente Medical Care Program Departments of Pediatrics Vaccine Study Group1

1 From the Departments of Pediatrics, Kaiser Permanente Medical Care Program, Northern California Region

The b-CAPSA I capsular polysaccharide vaccine for Haemophilus influenzae type b was given to 87,541 children 2 through 5 years of age in the Kaiser Permanente Medical Care Program, and the children were then followed using a multiple modality surveillance. Phase 1 consisted of 24-hour recall of immediate side effects which were recorded on questionnaires given to families of 13,500 children. Local side effects were found to be uncommon: 2.3% had a temperature of ge38.3°C (ge101°F); 4.8% had local erythema, 2.9% local swelling, and 12.6% local tenderness; two children had wheezing shortly after immunization. In Phase 2, 30 days after immunization, questionnaires were mailed to parents of all 87,541 children, who were asked to respond to questions about illnesses and health care. Phase 3 consisted of active surveillance of patient health care use by physicians and nurses during the 30 days after immunization. During the 30-day reporting periods, there were 40 hospitalizations, including one for wheezing and one for febrile seizure. Of the 40 hospitalizations, only the one for wheezing was believed by the admitting physician to be probably associated with vaccine administration. Three children had seizures within 30 days of immunization. None of the seizures was believed by the reporting physician to be associated with immunization. Adverse effects of the vaccine were mild, limited to local reactions and occasional temperature elevation; bronchospasm after immunization occurred rarely.

Key Words: Haemophilus influenzae • type b • immunization • capsular polysaccharide vaccine

Accepted on October 29, 1986




This article has been cited by other articles:


Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
A. K.C. Leung, A. S.K. Chiu, and T. O. Siu
Subcutaneous versus intramuscular administration of Haemophilus influenzae type b vaccine
The Journal of the Royal Society for the Promotion of Health, April 1, 1989; 109(2): 71 - 73.
[Abstract]

Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
A. K.C. Leung and T. Jadavji
Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease
The Journal of the Royal Society for the Promotion of Health, October 1, 1988; 108(5): 180 - 181.